Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

• Status: Terminated
• Trial end date: 2003-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Pharmaceutical Solutions; Ribavirin

Criteria

INCLUSION CRITERIA:

• 2 years of age or older.

• Are not pregnant or breast-feeding and agree to use a reliable birth control method for the duration of the study.

• Are a blood or bone marrow transplant recipient.

• Have evidence of upper respiratory tract infection.

• Have nasopharyngeal-throat samples positive for RSV.

EXCLUSION CRITERIA:

• Are known to be HIV positive.

• Have pneumonia.

• Require a ventilator to breathe.

• Are pregnant.

• Are breast-feeding and are unwilling to stop breast-feeding.

• Are receiving treatment with certain other drugs for RSV.